Scientists just uncovered how to spot a devastating disease 25 years early, but only for this specific group
A real shot at proactive prevention strategies.
Get ready for some potentially life-changing news, especially if you’re an older woman, because a new blood test might just be able to determine your dementia risk a full 25 years before any symptoms even emerge. This is a huge breakthrough, offering a glimpse into the future of proactive health management.
According to the NY Post, new research from the University of California San Diego has pinpointed a specific biomarker protein called phosphorylated tau 217 (p-tau217). This protein, which is strongly linked to the early pathological processes of Alzheimer’s disease, has now been found to be deeply associated with future dementia risk.
To get to these findings, researchers delved into blood samples collected in the late 1990s from 2,766 participants in the Women’s Health Initiative Memory Study. These women, aged 65 to 79 at the study’s start, showed absolutely no signs of cognitive decline back then. The team then tracked these participants for up to 25 years.
The study unearthed some significant results
What they discovered was pretty stark: women who had higher levels of p-tau217 at the beginning of the study were significantly more likely to develop mild cognitive impairment and dementia later on. The study’s findings were officially published in JAMA Network Open, showcasing a clear and strong association.
Aladdin H. Shadyab, a UC San Diego associate professor of public health and medicine and the study’s first author, shared his thoughts on the discovery. He explained that the key takeaway is that this study suggests it might be possible to detect dementia risk two decades in advance using a simple blood test in older women.
He added that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms even begin. This long lead time could totally open the door to earlier prevention strategies and more targeted monitoring.
The risk relationship wasn’t uniform across the board
The study found that women over 70 with higher p-tau217 levels generally experienced “poorer cognitive outcomes” compared to those under 70. The same was true for women with the APOE ε4 gene, which is already a known risk factor for Alzheimer’s disease. Interestingly, p-tau217 was also a stronger predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy versus those who got a placebo.
Linda K. McEvoy, senior author and senior investigator at Kaiser Permanente Washington Health Research Institute, pointed out how promising these blood-based biomarkers are. She said they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests, which is huge for accelerating research and evaluating strategies to reduce dementia risk.
It’s important to note that blood tests for Alzheimer’s are still being studied. They aren’t currently recommended for screening in people without symptoms. More research is needed before this can be considered for widespread clinical use prior to any cognitive symptoms appearing. The researchers also noted that future studies should investigate how factors like genetics, hormone therapy, and age-related medical conditions, might interact with plasma p-tau217.
It’s also crucial to understand that this study focused exclusively on older women, so the findings might not necessarily apply to men or younger populations. The research also examined overall dementia outcomes rather than specific subtypes such as Alzheimer’s disease.
Have a tip we should know? [email protected]
